| SCHEDULE OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s
reportable segment for the periods presented:
SCHEDULE
OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
For The Three
Months Ended |
|
|
For The Nine
Months Ended |
|
| |
|
September 30, |
|
|
September 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue, net: |
|
$ |
10,373 |
|
|
$ |
8,756 |
|
|
$ |
28,537 |
|
|
$ |
29,504 |
|
| Less: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fixed |
|
|
1,754 |
|
|
|
1,736 |
|
|
|
5,220 |
|
|
|
5,120 |
|
| Variable |
|
|
1,439 |
|
|
|
1,581 |
|
|
|
4,579 |
|
|
|
6,298 |
|
| Operating and other expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales and marketing |
|
|
2,704 |
|
|
|
2,087 |
|
|
|
7,088 |
|
|
|
7,811 |
|
| Research and development |
|
|
160 |
|
|
|
150 |
|
|
|
461 |
|
|
|
500 |
|
| General and administrative |
|
|
6,716 |
|
|
|
2,057 |
|
|
|
12,143 |
|
|
|
7,268 |
|
| Interest & other
expense, net |
|
|
(15 |
) |
|
|
145 |
|
|
|
(33 |
) |
|
|
268 |
|
| (Benefit)
provision for income taxes |
|
|
(884 |
) |
|
|
(11 |
) |
|
|
(517 |
) |
|
|
7 |
|
| Segment net (loss) income |
|
|
(1,501 |
) |
|
|
1,011 |
|
|
|
(404 |
) |
|
|
2,232 |
|
| Reconciliation of profit
or loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss
on discontinued operations |
|
|
(109 |
) |
|
|
(100 |
) |
|
|
(327 |
) |
|
|
(314 |
) |
| Consolidated net
(loss) income |
|
$ |
(1,610 |
) |
|
$ |
911 |
|
|
$ |
(731 |
) |
|
$ |
1,918 |
|
|
| SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA |
SCHEDULE
OF RECONCILIATION OF ADJUSTED EBITDA
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
Three Months
Ended |
|
|
Nine Months
Ended |
|
| |
|
September
30, |
|
|
September
30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| (Loss) income from continuing
operations (GAAP Basis) |
|
$ |
(1,501 |
) |
|
$ |
1,011 |
|
|
$ |
(404 |
) |
|
$ |
2,232 |
|
| Depreciation and amortization |
|
|
141 |
|
|
|
111 |
|
|
|
386 |
|
|
|
307 |
|
| Stock-based compensation |
|
|
3,993 |
|
|
|
7 |
|
|
|
4,001 |
|
|
|
31 |
|
| Non-recurring legal expenses |
|
|
234 |
|
|
|
- |
|
|
|
614 |
|
|
|
- |
|
| Severance & related expense |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
692 |
|
| Asset impairment - lab supplies |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
198 |
|
| Loss on sale of asset |
|
|
104 |
|
|
|
- |
|
|
|
104 |
|
|
|
- |
|
| Lab supplies write-off |
|
|
- |
|
|
|
- |
|
|
|
217 |
|
|
|
- |
|
| Taxes (benefit) expense |
|
|
(884 |
) |
|
|
(11 |
) |
|
|
(517 |
) |
|
|
7 |
|
| Note payable interest |
|
|
- |
|
|
|
30 |
|
|
|
- |
|
|
|
156 |
|
| Other income/expense, net |
|
|
(15 |
) |
|
|
10 |
|
|
|
(33 |
) |
|
|
25 |
|
| Change in fair value
of note payable |
|
|
- |
|
|
|
105 |
|
|
|
- |
|
|
|
87 |
|
| Adjusted EBITDA |
|
$ |
2,072 |
|
|
$ |
1,263 |
|
|
$ |
4,368 |
|
|
$ |
3,735 |
|
|